More than 450 companies adopt Veeva RIM to accelerate regulatory submissions
Veeva Systems announced today that more than 450 companies, including 19 of the world’s top 20 biopharmas, are now using Veeva RIM to streamline regulatory information management (RIM). The milestone reflects growing momentum for a unified, cloud-based platform to reduce cycle times and strengthen collaboration with health authorities worldwide.
Veeva said adoption is being fuelled by new product innovations and expanded industry partnerships. Recent collaborations with Accumulus Technologies and DNAnexus aim to modernise connectivity with multi-agency platforms, enabling faster, more compliant submissions.
Marc Gabriel, vice president of regulatory at Veeva, said: “Regulatory teams are under pressure to move faster without compromising compliance. Veeva RIM is helping companies reduce rework, accelerate time to market, and improve collaboration across global teams and agencies.”
Veeva Submissions Publishing is one area of strong uptake, with more than 85 organisations using its continuous publishing capability to eliminate bottlenecks and accelerate submissions.
Francisco Nogueira, CEO of Accumulus Technologies, added: “Our partnership with Veeva connects the Accumulus platform to Veeva RIM for greater interoperability. By enabling information to be shared instantly with more than 70 regulatory agencies worldwide, we can help customers bring treatments to patients faster.”
DNAnexus is also joining forces with Veeva to integrate its Trusted Regulatory Spaces (TRS) with Veeva RIM. “This integration will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals,” said Thomas Laur, CEO of DNAnexus.
The company said the goal is to create an end-to-end regulatory environment where data flows seamlessly between life sciences companies and health authorities, reducing inefficiencies that have long slowed product approvals.
Veeva RIM sits within the Veeva Development Cloud, which brings together clinical, regulatory, quality, and safety applications on a single platform. Veeva said this unified approach allows companies to manage the entire product lifecycle with greater transparency and speed.




